A study assessing the combination of Dacomitinib and Crizotinib in patients with previously treated metastatic HER2-negative breast cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 03 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Feb 2021 New trial record
27 Jan 2021 According to a Celcuity media release, the company will obtain interim results 12 to 15 months after the protocol is activated and final results 12-15 months later. Celcuity expects enrollment to begin in the second quarter of 2021.
27 Jan 2021 According to a Celcuity media release, Sarah Cannon Research Institute will serve as the sponsor and Erika Hamilton, MD, will serve as the principal investigator of this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com